ExpreS2ion Biotech


Upcoming events

Latest press releases

Strong preclinical immunization data for the ABNCoV2 cVLP-based COVID-19 vaccine published in Nature Communications

Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the publication of strong virus neutralization properties in animal proof-of-concept data for ABNCoV2, a unique capsid virus like particle (cVLP) based COVID-19 vaccine coated with ExpreS2-made SARS-CoV-2 antigens, in the esteemed scientific journal Nature Communications. The ABNCoV2 COVID-19 vaccine is the result…

Read more

ExpreS2ion strengthens its organization to further accelerate its pipeline project development

This is a regulatory release

Hørsholm, Denmark, January 11, 2021 – ExpreS2ion Biotech Holding AB hereby announces that its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is reorganizing the company’s top management to reflect its increased strategic focus on pipeline development. Several appointments within research and development will ensure the advancement of ExpreS2ion’s development projects towards clinical investigations, with the first fully controlled…

Read more

View all